These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11854425)

  • 1. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.
    Blanpain C; Vanderwinden JM; Cihak J; Wittamer V; Le Poul E; Issafras H; Stangassinger M; Vassart G; Marullo S; Schlndorff D; Parmentier M; Mack M
    Mol Biol Cell; 2002 Feb; 13(2):723-37. PubMed ID: 11854425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
    Szabo I; Wetzel MA; Zhang N; Steele AD; Kaminsky DE; Chen C; Liu-Chen LY; Bednar F; Henderson EE; Howard OM; Oppenheim JJ; Rogers TJ
    J Leukoc Biol; 2003 Dec; 74(6):1074-82. PubMed ID: 12972507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I-TAC/CXCL11 is a natural antagonist for CCR5.
    Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
    J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S; Nakajima R; Takamune N; Shoji S
    J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
    Owais M; Arya SK
    J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
    Ji C; Brandt M; Dioszegi M; Jekle A; Schwoerer S; Challand S; Zhang J; Chen Y; Zautke L; Achhammer G; Baehner M; Kroetz S; Heilek-Snyder G; Schumacher R; Cammack N; Sankuratri S
    Antiviral Res; 2007 May; 74(2):125-37. PubMed ID: 17166600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte chemoattractant protein-2 (CC chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1 via CC chemokine receptor 5.
    Yang OO; Garcia-Zepeda EA; Walker BD; Luster AD
    J Infect Dis; 2002 Apr; 185(8):1174-8. PubMed ID: 11930329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivities of pyrogenic chemokine fevers to CC chemokine receptor 5 antibodies.
    Tavares E; Miñano FJ
    Fundam Clin Pharmacol; 2004 Apr; 18(2):163-9. PubMed ID: 15066130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The seventh transmembrane domain of cc chemokine receptor 5 is critical for MIP-1beta binding and receptor activation: role of MET 287.
    Youn BS; Yu KY; Alkhatib G; Kwon BS
    Biochem Biophys Res Commun; 2001 Mar; 281(3):627-33. PubMed ID: 11237703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
    Lee B; Sharron M; Blanpain C; Doranz BJ; Vakili J; Setoh P; Berg E; Liu G; Guy HR; Durell SR; Parmentier M; Chang CN; Price K; Tsang M; Doms RW
    J Biol Chem; 1999 Apr; 274(14):9617-26. PubMed ID: 10092648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES.
    Nisius L; Rogowski M; Vangelista L; Grzesiek S
    Protein Expr Purif; 2008 Oct; 61(2):155-62. PubMed ID: 18588983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice.
    Uekusa Y; Yu WG; Mukai T; Gao P; Yamaguchi N; Murai M; Matsushima K; Obika S; Imanishi T; Higashibata Y; Nomura S; Kitamura Y; Fujiwara H; Hamaoka T
    Cancer Res; 2002 Jul; 62(13):3751-8. PubMed ID: 12097285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
    Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
    J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis.
    Crane IJ; Xu H; Wallace C; Manivannan A; Mack M; Liversidge J; Marquez G; Sharp PF; Forrester JV
    J Leukoc Biol; 2006 Mar; 79(3):435-43. PubMed ID: 16365158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.